摘要
为评价在中国医疗环境下评估麝香通心滴丸联合西药常规治疗与西药常规治疗相比对冠心病患者的经济性。该研究从医保角度出发,基于麝香通心滴丸联合西药常规治疗和西药常规治疗比较的Meta分析结果构建Markov模型。试验组均为麝香通心滴丸联合西药常规治疗,对照组均为西药常规治疗。运用Treeage pro对2种治疗方案进行成本-效用分析和敏感性分析。模型模拟30周期后,麝香通心滴丸联合西药常规治疗方案的总成本和健康产出分别为237795.73元和16.36QALYs;西药常规治疗方案的总成本和健康产出分别为247396.55元和13.59QALYs。相比对照组,试验组为长期成本更低、健康产出更高的治疗方案,具有成本-效用优势和药物经济学优势的治疗方案,敏感性分析结果显示该结论较为稳定。综上所述,认为在治疗冠心病方面,相比西药常规治疗,麝香通心滴丸联合西药常规治疗为具有药物经济学优势的治疗方案。
This research was to evaluate the economics of Shexiang Tongxin Dropping Pills combined with conventional therapy for patients with coronary heart disease(CHD)in Chinese medical environment.From the perspective of medical insurance,a Markov model was established in this study based on the results of Meta-analysis comparing the effectiveness and safety of Shexiang Tongxin Dripping Pills combined with conventional treatment and conventional treatment alone.The experimental group was treated with She-xiang Tongxin Dropping Pills combined with conventional Western medicine treatment,while the control group was treated with conventional Western medicine treatment alone.The cost-utility analysis and sensitivity analysis were performed for the two regimens using Treeage pro.After 30 cycles of model simulation,according to the results of Markov model,the total cost and health output were CNY 237795.73 and 16.36 QALYs(the quality adjusted life years,QALYs),respectively for Shexiang Tongxin Dropping Pills combined with conventional Western medicine treatment,CNY 247396.55 and 16.36 QALYs respectively for the conventional Western medicine treatment alone.Compared with the conventional treatment alone,the Shexiang Tongxin Dropping Pills combined with conventional treatment had lower long-term cost and higher health output,with advantages of cost-utility and pharmacoeconomic advantages.The sensitivity analysis results showed that the conclusion was relatively stable.Based on the above results,it is considered that compared with the conventional Western medicine alone,Shexiang Tongxin Dropping Pill combined with conventional Western medicine is a treatment regimen with pharmacoeconomic advantages for the treatment of CHD.
作者
潘婕
王志恒
王晓梅
左凯妮
周佳孟
王葳
卢斯琪
朱文涛
张立晶
PAN Jie;WANG Zhi-heng;WANG Xiao-mei;ZUO Kai-ni;ZHOU Jia-meng;WANG Wei;LU Si-qi;ZHU Wen-tao;ZHANG Li-jing(School of Management,Beijing University of Chinese Medicine,Beijing 100029,China;Department of Cardiology,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2021年第7期1832-1838,共7页
China Journal of Chinese Materia Medica
基金
中央高校基本科研业务费专项(2020-JYB-ZDGG-072)。
关键词
冠心病
成本-效用分析
MARKOV模型
麝香通心滴丸
coronary heart disease(CHD)
cost-utility analysis
Markov model
Shexiang Tongxin Dropping Pills
